Core Viewpoint - A lawsuit has been filed against Flywire Corporation and its senior executives for potential violations of federal securities laws, with claims related to the company's misrepresentation of its revenue growth and the impact of visa and permit restrictions on its business [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Eastern District of New York, titled Hickman v. Flywire Corp., et al., No. 1:25-cv-04110 [2]. - Investors have until September 23, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - Flywire operates as a payments-enablement and software company, primarily serving the education sector, which is heavily reliant on international student enrollments [3]. - The company has faced challenges due to tightening student visa and permitting rules implemented by the Canadian and Australian governments in late 2023 and early 2024 [3]. Group 3: Allegations and Impact - The lawsuit alleges that Flywire overstated the strength and sustainability of its revenue growth while downplaying the negative impacts of visa-related restrictions [4]. - On February 25, 2025, Flywire disclosed significant deterioration in its education sector business, citing "double digit declines in student visa issuance" and anticipated continued restrictions [5]. - Following this announcement, Flywire's stock price fell approximately 37%, from $17.64 per share to $11.05 per share within a day [5].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., No. 25-cv-01596, with investors having until September 22, 2025, to seek lead plaintiff status [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors, leading to a significant stock price decline [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, resulting in a 38% drop in stock price from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization, caused another 38% decline in stock price from $12.79 to $7.95 per share [6].

Core Viewpoint - A class action securities lawsuit has been filed against CTO Realty Growth, Inc. alleging securities fraud that affected investors between February 18, 2021, and June 24, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that CTO Realty Growth, Inc. misled investors regarding the sustainability of its dividends [2]. - It is alleged that the company employed deceptive practices to inflate its adjusted funds from operations and misrepresent the profitability of its Ashford Lane property [2]. - Consequently, the business and financial prospects of CTO Realty Growth were overstated, leading to materially false and misleading public statements [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until October 7, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - The complaint against Alto alleges violations of federal securities laws due to misleading statements regarding the effectiveness of ALTO-100 in treating Major Depressive Disorder (MDD) and the overstated prospects of the company's business and financial performance [2]. Group 1: Company Performance and Stock Impact - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in a Phase 2b trial for MDD, leading to a significant stock price drop of $10.17 per share, or 69.99%, closing at $4.36 on October 23, 2024 [3]. - Following the announcement, Jeffries reduced its price target for Alto from $33 to $17, indicating concerns about the company's biomarker approach to central nervous system disorders and psychiatry [4]. Group 2: Legal Proceedings - The lead plaintiff in the class action lawsuit is the investor with the largest financial interest, who will oversee the litigation on behalf of the class [5]. - The law firm Faruqi & Faruqi encourages individuals with information regarding Alto's conduct to come forward, including whistleblowers and former employees [6].

Core Viewpoint - A class action lawsuit has been filed against SelectQuote, Inc. for alleged violations of federal securities laws, impacting investors who purchased the company's securities between September 9, 2020, and May 1, 2025 [1][2]. Summary by Sections Class Definition - The lawsuit aims to recover damages for all individuals and entities that acquired SelectQuote securities during the specified Class Period [2]. Case Details - The complaint alleges that SelectQuote's executives made materially false and misleading statements and failed to disclose significant adverse facts about the company's operations, including: 1. Directing Medicare beneficiaries to plans that compensated SelectQuote rather than providing unbiased comparisons [3]. 2. Receiving illegal kickbacks to steer beneficiaries to certain insurers [3]. 3. Non-compliance with applicable laws and regulations, making the company vulnerable to legal sanctions [3]. 4. Misleading positive statements regarding the company's business and prospects [3]. Stock Price Impact - Following the news of the lawsuit, SelectQuote's stock price dropped by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025, with unusually high trading volume [4]. Next Steps - Investors who suffered losses in SelectQuote have until October 10, 2025, to request appointment as lead plaintiff in the class action [5]. Legal Representation - The law firm Bronstein, Gewirtz & Grossman operates on a contingency fee basis, meaning they will only collect fees if the case is successful [6][7].

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of Designer Brands Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] - On June 10, 2025, Designer Brands announced the withdrawal of its 2025 guidance due to a soft start to the year, an unpredictable macro environment, and deteriorating consumer sentiment [3] - Following the announcement, Designer Brands' stock price fell by $0.68 per share, or 18.23%, closing at $3.05 per share on the same day [3] Group 2 - Designer Brands is focusing on amplifying value in retail channels, preserving margins, controlling costs, and mitigating tariff impacts in response to market volatility [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Tronox Holdings plc and its officers or directors, following disappointing financial results and a significant stock price drop [1][3]. Financial Performance - Tronox reported revenue of $731 million for Q2 2025, which is a 10.9% decline year-over-year and fell short of consensus estimates by $53.45 million [3]. - The company attributed the revenue decline to delays in Brazil's anti-dumping investigation affecting sales in that region [3]. Stock Market Reaction - Following the release of the financial results, Tronox's stock price decreased by $1.95 per share, or 37.94%, closing at $3.19 per share on July 31, 2025 [4]. Company Response - Tronox has revised its 2025 financial outlook and is taking proactive measures, including adjusting capital allocation priorities to enhance long-term shareholder value [3].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against GeneDx Holdings Corp. for possible violations of federal securities laws and unlawful business practices, following allegations of widespread fraud reported by Grizzly Research [1][3]. Summary by Relevant Sections Legal Investigation - The law firm is encouraging GeneDx stockholders who have suffered losses to contact them to discuss their legal rights and options [1][4]. - The investigation is focused on whether GeneDx has engaged in fraudulent activities that could impact its stockholders [1]. Allegations of Fraud - Grizzly Research published a report claiming that GeneDx's growth is largely an illusion, driven by fraudulent schemes aimed at exploiting Medicaid and Medicare systems to inflate revenue [3]. - The report alleges that GeneDx has used a practice known as "code stacking" to bill insurance providers for services that do not meet required criteria [3]. - It was noted that CEO Katherine Stueland and CFO Kevin Feeley have sold their shares immediately upon vesting, suggesting insider knowledge of imminent risks [3]. Stock Market Impact - Following the release of the Grizzly report, GeneDx's stock price fell by $4.84, or 6.72%, closing at $67.18 per share on February 5, 2025 [3].

Core Viewpoint - DJS Law Group is investigating Agilon Health, Inc. for potential violations of securities laws following significant leadership changes and a withdrawal of earnings guidance, which led to a sharp decline in the company's stock price [1][2]. Investigation Details - The investigation centers on whether Agilon made misleading statements or failed to disclose critical information to investors [2]. - On August 4, 2025, Agilon announced the resignation of President, CEO, and Board Director Steven Sell, which coincided with the release of its second quarter 2025 earnings results [2]. - Agilon also withdrew its previous full year 2025 earnings guidance, resulting in a more than 27% drop in shares during after-hours trading [2]. Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, representing large hedge funds and alternative asset managers [4].

Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's initial public offering and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Alto common stock related to the initial public offering on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [2]. - The complaint alleges that the company made false statements regarding the effectiveness of its product pipeline, ALTO-100, in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until September 19, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [5].